PDC*line Pharma

Biotech company developing a new class of potent and scalable active off-the-shelf cancer vaccine

Total raised

€26M

€25,600,000

Funding rounds

Investors

distinct backers

Active since

2021-12

latest 2024-01

Funding by year

EUR raised per year

Medium confidence

Raise-next likelihood20

base rate 30% for Other

Exit likelihood12

base rate 12% (2+ rounds)

Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

2 rounds

Date	Stage	Amount	Investors
2024-01-18	Other	€8.1M	—	View deal →
2021-12-06	Series B	€18M	Alpha Holdings,Brain Asset Management,Hansongneotech Co.,Korea Investment Partners,Noshaq Group,Sambrinvest+3 more	View deal →

same sector or country